Search - tctmd.com

Displaying 81 - 98 of 98

Sort: Relevancy | Date

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

News Conference News ACC 2017

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Caitlin E. Cox

March 18, 2017

News Conference News ACC 2017

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Todd Neale

March 18, 2017

News Daily News

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

Todd Neale

March 07, 2017

News Daily News

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

L.A. McKeown

March 02, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Conference News ISET 2017

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

Caitlin E. Cox

February 10, 2017

Presentation JIM 2017

The EluNIR clinical program: BIONICS and NIREUS - One Year Follow Up

Presenter: Giuseppe Musumeci

February 09, 2017

News Daily News

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

L.A. McKeown

February 08, 2017

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Daily News

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

Michael O'Riordan

February 02, 2017

News Daily News

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Michael O'Riordan

January 20, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

News Conference News AHA 2014

DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation

Yael L. Maxwell

November 16, 2014

News Daily News

Ticagrelor More Effective Than Clopidogrel in ACS-With No Extra Bleeding

Kim Dalton

August 30, 2009

CME

Advertisement

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

iFR Matches FFR for Clinical Outcomes in Patients With Intermediate Lesions

Replacing Aspirin With Low-Dose Rivaroxaban for Post-ACS Therapy Appears Safe

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

Length Matters: More Adverse Events With Absorb BVS at 1 Year in Long Lesions

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Percutaneous Bypass for Long, Complex SFA Lesions Holds Up Well to 6 Months: DETOUR I Study

The EluNIR clinical program: BIONICS and NIREUS - One Year Follow Up

10-Year Follow-up of Early DES Shows Steady Risk of Late Events

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Device, Operator, or Lesion: What Affects Long-term Outcomes With Bioresorbable Scaffolds?

TWENTE: Resolute and Xience Stents Show Comparable Outcomes up to 5 Years

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation

Ticagrelor More Effective Than Clopidogrel in ACS-With No Extra Bleeding

Optimizing Outcomes During and After PCI: From Intravenous to Oral Platelet Inhibition

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content